Effects of Dynorphin 1-13 on Heroin Addiction - 1

University of Minnesota (UMN)

Status and phase: Completed; Phase 2

Conditions: Substance Withdrawal Syndrome; Opioid-Related Disorders

Treatments: Drug: Dynorphin 1 - 13

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000244

R01DA008067 (U.S. NIH Grant/Contract)

R01-08067-1

NIDA-08067-1

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.

Full description

Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

opiate addict between the ages of 18-55

Exclusion criteria

Regular abuse of other drugs, unstable medical conditions